2011, Number 3
PDF size: 64.61 Kb.
ABSTRACTThe atrial fibrillation (AF) is present in 2% of the population will double in the next 50 years due to aging of the same, with high rates of death, thromboembolic events, reduced quality of life, increases 5 times the stroke, because third hospitalizations. Heart failure agrees 30% of these patients. Valvulopathy found in 30% of rheumatic was common, now rare. Thyroid dysfunction can cause subclinical dysfunction can still contribute. Of the patients attending cardiology outpatient some arrhythmia between June 1, 2010 through March 28, 2011, 19 (34.5%) were diagnosed with AF, 12 women (62.5%) and 7 (37.5%) men, 79% are over 60 years. The most antiarrhythmic beta-blocker used was the 57.8%, followed by 36.8% digoxin and amiodarone in 21%. Monotherapy in 52.6% dual therapy in 36.8% only in 10.5 triple. To embolism prophylaxis with acid acetylsalicylic was used in 63% and oral anticoagulants in 36.8%. The AF is asymptomatic and undiagnosed for a long time, patients are not going to go to hospital and therefore not going to change its natural history, systematic search diagnosis will help to early diagnosis. The new antithrombotic and antiarrythmic emerging safer, helping to improve clinical outcome. Hence the importance of early diagnosis.
Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-521.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803-2817.
Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47: 285-289.
Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953.
Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-1539.
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042-1046.
Stewart S, Hart CL, Hole DJ, McMurray JJ. A population based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C et al. Atrial fibrillation in strokefree patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125-2132.
Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967-975.
Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119: e1-e19.
Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al. The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-1816.
Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 2009; 30: 1411-1420.